Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients with Chronic Myeloid Leukemia:a Multicenter Retrospective Study in Hubei Province,China

Dasatinib is a second-generation tyrosine kinase inhibitor (TKI)and it could be used as a second-line treatment for patients with chronic myeloid leukemia (CML).Yinishu,a generic dasatinib made in China,was approved by the China Food and Drug Administration in 2013 and it costs much less than the patented dasatinib SPRYCEL.The present study aimed to examine the efficacy and safety of Yinishu as a second-line treatment for CML by comparing the baseline clinical characteristics,rates of adverse events and efficacy between Yinishu and SPRYCEL groups. The results showed that there were no significant differences in the rates of optimal response between Yinishu and SPRYCEL for patients who started second-line treatment because of treatment failure.For patients who started second-line treatment because of intolerance of first-line treatment, their levels of BCR-ABL1/ABL1 on the international scale (BCR-ABL^IS)was maintained very low throughout the course of Yinishu treatment.Drug-related adverse events occurred with the same frequency in these two groups.It was confirmed that Yinishu was effective and safe as a second- line treatment for CML patients.Yinishu may be more suitable for patients who are economically unable to pay for the patented dasatinib SPRYCEL.

Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer

BACKGROUND There is no standard therapy for second-line treatment of gemcitabine-refractory pancreatic cancer patients with poor performance status.A combination of chemotherapy drugs 5-fluorouracil(5-FU),leucovorin,irinotecan,and oxaliplatin(FOLFIRINOX)or 5-fluorouracil/leucovorin plus nanoliposomal irinotecan can be considered as second-line treatment for such patients;however,due to toxicity,none of the regimens are recommended for patients with poor performance.Capecitabine or S-1 has relatively low toxicity and can be considered a treatment option for gemcitabine-refractory pancreatic cancer.AIM To investigate the efficacy and toxicity of oral chemotherapy as second-line treatment in patients with pancreatic cancer.METHODS Patients who had progressive disease after first-line gemcitabine-based chemotherapy were retrospectively analyzed between January 2011 and December 2018.They were treated with capecitabine or S-1 as the second-line treatment.Capecitabine was administered as a 2500 mg/m2 divided dose on days 1-14,followed by a 1-wk rest.S-1 was taken orally based on the patient’s body surface area for 28 d,followed by 2-wk of rest.Progression-free survival and overall survival were used to compare efficacy of capecitabine and S-1.RESULTS Of the 81 patients,41 were treated with capecitabine and 40 with S-1.The median time to treatment failure in both groups was 1.5 mo(P=0.425).The objective response rate was similar in the two groups:9.8%with capecitabine and 2.5%with S-1(P=0.359).Median progression-free survival was longer in the S-1 group than in the capecitabine group(S-12.7 mo,capecitabine 2.0 mo,P=0.003).There was no significant difference in the median overall survival between the capecitabine and S-1 groups(4.3 mo vs 5.0 mo,P=0.092).Grade 3 or 4 hand-foot syndrome was significantly more common in the capecitabine group than in the S-1 group(14.6%vs 0%,P=0.026).CONCLUSION Capecitabine or S-1 can be used as a second-line treatment for patients with advanced pancreatic cancer with poor performance status after progression to a gemcitabine-based regimen.

Second-line treatment of advanced hepatocellular carcinoma:Time for more individualized treatment options?

Hepatocellular carcinoma(HCC)is the most frequently diagnosed primary tumor of the liver and is usually detected as advanced disease.It is an aggressive disease that often progresses rapidly when it fails to respond to treatment.As such,patients have limited opportunities to try different subsequent-line treatment regimens.In the last 5 years,the number of agents and/or regimens available for the treatment of advanced HCC has significantly increased,which has made treatment choices for this patient population increasingly complex.In the secondline setting,several phase III trials of regorafenib(RESORCE),ramucirumab(REACH/REACH-2),and cabozantinib(CELESTIAL)have demonstrated clinically meaningful survival benefits in patients with the disease.However,the median overall survival of patients with advanced HCC remains unchanged at approximately 12 mo from the start of systemic second-line therapy,with a limited duration of response.Evidence from the REACH/REACH-2 trials demonstrated for the first time that baseline alpha-fetoprotein(AFP)levels can be used as an identification factor to select those who are likely to benefit the most from ramucirumab treatment.Ramucirumab is both well tolerated and efficacious and has a clinically acceptable safety profile.Therefore,it should be considered an option for patients with AFP levels≥400 ng/mL.

Combination chemotherapy with irinotecan and cisplatin as second-line treatment for small cell lung cancer

Objective： To evaluate the efficacy and safety of irinotecan （CPT-11） plus cisplatin （DDP） in patients with small cell lung cancer （SCLC） as second-line chemotherapy. Methods： Patients received irinotecan 60 mg/m^2 on days 1, 8, 15, and cisplatin 25 mg/m^2 on days 1-3, every 28 days one cycle. Response was evaluated every two cycles and patients were follow-up for two years or until death. Results： Among the 28 evaluable patients, there were 1 CR, 7 PR, 8 SD and 12 PD. The response rate was 28.6% （8/28）. Median time to progression （TTP） was 3.2 （0.8-5.6） months. Median survival after second-line treatment was 7.5 （1.5-31） months and overall survival was 15 （2.3-43.5） months. The most common adverse effect was hematological toxicity with 36.7% （11/30）, grades Ⅲ-Ⅳ neutroperia. Hepatic toxicity was another major side effect. Only one patient developed grade Ⅲ diarrhea. Conclusion： The combination of irinotecan and cisplatin is feasible, effective, and safe for SCLC as second-line treatment.

Influence of High Temperature Treatment on the Performance of Nickel-Induced Laterally Crystallized Thin Film Transistors

Well known for their good performance,thin film transistors (TFTs) with active layers which were nickel induced laterally crystallized,are fabricated by conventional process of dual gate CMOS.The influence of pre high temperature treatment of device fabrication on the performance of TFTs is also investigated.The experiment shows that the high temperature treatment affects the performance of the devices strongly.The best performance is obtained by adopting pre treatment of 1000℃.The mobility of 314cm 2/(V·s) is obtained at NMOS TFTs with pre treatment of 1000℃,which is 10% and 22% higher than that treated at 1100℃ and without pre high temperature treatment,respectively.A maximum on/off current ratio of 3×10 8 is also obtained at 1000℃.Further investigation of uniformity verifies that the result is reliable.

Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line

Worldwide prevalence of Helicobacter pylori(H.pylori) infection is approximately 50%,with the highest being in developing countries.We compared cure rates and tolerability(SE) of second-line anti-H.pylori levofloxacin/amoxicillin(LA)-based triple regimens vs standard quadruple therapy(QT).An English language literature search was performed up to October 2010.A meta-analysis was performed including randomized clinical trials comparing 7-or 10-d LA with 7-d QT.In total,10 articles and four abstracts were identified.Overall eradication rate in LA was 76.5%(95% CI:64.4%-97.6%).When only 7-d regimens were included,cure rate was 70.6%(95% CI:40.2%-99.1%),whereas for 10-d combinations,cure rate was significantly higher(88.7%;95% CI:56.1%-109.9%;P < 0.05).Main eradication rate for QT was 67.4%(95% CI:49.7%-67.9%).The 7-d LA and QT showed comparable efficacy [odds ratio(OR):1.09;95% CI:0.63-1.87],whereas the 10-d LA regimen was significantly more effective than QT(OR:5.05;95% CI:2.74-9.31;P < 0.001;I 2 = 75%).No differences were reported in QT eradication rates among Asian and European studies,whereas LA regimens were more effective in European populations(78.3% vs 67.7%;P = 0.05).Incidence of SE was lower in LA therapy than QT(OR:0.39;95% CI:0.18-0.85;P = 0.02).A higher rate of side effects was reported in Asian patients who received QT.Our findings support the use of 10-d LA as a simple second-line treatment for H.pylori eradication with an excellent eradication rate and tolerability.The optimal second-line alternative scheme might differ among countries depending on quinolone resistance.

Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication

AIM: To compare the efficacy of 14- and 7-d bismuthbased quadruple therapies as second-line eradication treatment for Helicobacter pylori(H.pylori) infection.METHODS: Between 2004 and 2014,the medical records of 790 patients who had experienced failure of first-line proton pump inhibitor(PPI)-based eradication therapy and were then treated with bismuth-based quadruple therapy were retrospectively reviewed.Those who received bismuth-based quadruple therapy [PPI,bismuth,metronidazole,and tetracycline(PBMT)] for either 7 d or 14 d were assigned to a PBMT-7 group(n = 543) or a PBMT-14 group(n = 247),respectively.The eradication rates for both groups were determined by intention-to-treat(ITT) and per-protocol(PP) analyses.ITT analysis compared the treatment groups as originally allocated while the PP analysis including only those patients who had completed the treatment as originally allocated.Successful eradication therapy for H.pylori infection was defined as a negative 13C-urea breath test 4 wk after the end of eradication treatment.RESULTS: The overall ITT eradication rate was 69.1%(546/790).Final ITT eradication rates were 67.4%(366/543; 95%CI: 63.1%-71.7%) in the PBMT-7 group and 72.8%(180/247; 95%CI: 67.4%-78.2%) in the PBMT-14 group(P = 0.028).The overall PP eradication rate was 80.0%(546/682),and the final PP eradication rates were 78.2%(366/468; 95%CI: 72.1%-84.0%) in the PBMT-7 group and 84.1%(180/214; 95%CI: 76.8%-90.8%) in the PBMT-14 group(P = 0.009).The H.pylori eradication rates in the PBMT-14 group weresignificantly higher than in the PBMT-7 group according to both ITT(P = 0.028) and PP analysis(P = 0.009).Compliance was similar in both groups(PBMT-7 group: 97.9%; PBMT-14 group: 96.4%).Adverse event rates were 10.7%(51/478) and 17.1%(38/222) in the PBMT-7 and PBMT-14 groups,respectively(P = 0.487).CONCLUSION: The 14-d bismuth-based quadruple therapy is a significantly more effective second-line eradication treatment for H.pylori infection than the 7-d alternative.

Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication

AIM: To evaluate the efficacy of the 14-d moxifloxacinbased triple therapy for the second-line eradication of Helicobacter pylori(H. pylori) infection.METHODS: Between 2011 and 2013, we conducted a retrospective review of the medical records of 160 patients who had experienced failure of their first-line proton pump inhibitor-based eradication therapy and subsequently received the moxifloxacin-based triple therapy as a second-line eradication treatment regimen. The patients who were treated with the moxifloxacinbased triple therapy(oral 20 mg rabeprazole b.i.d., 1000 mg amoxicillin b.i.d., and 400 mg moxifloxacin q.d.) for 7 d were assigned to the RAM-7 group(n = 79) while those who took them for 14 days were assigned to RAM-14 group(n = 81). The eradication rates for both groups were determined by intentionto-treat(ITT) and per-protocol(PP) analyses. ITT analysis compared the treatment groups as originally allocated while the PP analysis including only those patients who had completed the treatment as originally allocated. Successful eradication therapy for H. pylori infection was defined as the documentation of a negative 13C-urea breath test 4 wk after the end of the eradication treatment.RESULTS: The overall ITT eradication rate was 76.2%(122/160). The final ITT eradication rates were 70.8%(56/79; 95%CI: 63.3%-77.1%) in the RAM-7 group and 81.4%(66/81; 95%CI: 74.6%-88.3%) in the RAM-14 group(P = 0.034). The overall PP eradication rate was 84.1%(122/145), and the final PP eradication rates were 77.7%(56/72; 95%CI: 70.2%-85.3%) in the RAM-7 group and 90.4%(66/73; 95%CI: 82.8%-98.1%) in the RAM-14 group(P = 0.017). The H. pylori-eradication rates in the RAM-14 group were significantly higher compared with that of the RAM-7 group according to both the ITT(P = 0.034) and the PP analyses(P = 0.017). Both groups exhibited good treatment compliance(RAM-7/RAM-14 group: 100%/100%). The adverse event rates were19.4%(14/72)and 20.5%(15/73)in the RAM-7 and RAM-14 groups,respectively(P=0.441).Adverse events occurred in 14 of the 72 patients(19.4)in the RAM-7 group and in 15 of the 73 patients(20.5)in the RAM-14 group.No statistically significant differences(P=0.441)were observed.CONCLUSION:The 14-d moxifloxacin-based triple therapy is a significantly more effective secondline eradication treatment as compared to the 7-d alternative for H.pylori infection in South Korea.

Comparison of surgical intervention with functional treatment for acute ruptures of lateral ankle ligmant:a meta-analysis

Objective:To compare the effect of surgical intervention on functional treatment.Methods: By searching the MEDLINE(1966 to October 2011),EMBASE(1980 to October 2011),the Chinese Biomedical Database Databases(1980 to October 2011),a total of 9 related RCT studies comparing surgical intervention with functional treatment were included in our study.RevMan software was taken to analyze the data.Results:These 9 studies Involved a total of 1 268 mostly young adults,including 580 patients with surgical treatment and 688 patients with functional treatment.The results showed the stability of ankle activity in surgical treatment group was better than that in functional treatment group,with the OR and 95%CI of 0.72(0.52-0.99).No significant difference was found in the recurrence of the surgical and functional group.However, the movement disorder in the surgical treatment suggested increased risk than that in functional group,with the OR and 95%CI of 2 39(0.98-5.85).Surgical group found more complication than the function group,such as deep vein thrombosis,deep venous thrombosis,tenderness of scar and sensory loss.Conclusions:In conclusion,our finding showed that surgical treatment could gain better efficacy than functional treatment,but may bring more complication.Therefore,further large sample size RCT is warranted.

Lateral epicondylitis:New trends and challenges in treatment

Lateral epicondylitis(LE)is a chronic aseptic inflammatory condition caused by repetitive microtrauma and excessive overload of the extensor carpi radialis brevis muscle.This is the most common cause of musculoskeletal pain syndrome in the elbow,inducing significant pain and limitation of the function of the upper limb.It affects approximately 1-3%of the population and is frequently seen in racquet sports and sports associated with functional overload of the elbow,such as tennis,squash,gymnastics,acrobatics,fitness,and weight lifting.Typewriters,artists,musicians,electricians,mechanics,and other professions requiring frequent repetitive movements in the elbow and wrists are also affected.LE is a leading causation for absence from work and lower sport results in athletes.The treatment includes a variety of conservative measures,but if those fail,surgery is indicated.This review summarizes the knowledge about this disease,focusing on risk factors,expected course,prognosis,and conservative and surgical treatment approaches.

Fascia- vs vessel-oriented lateral lymph node dissection for rectal cancer: Short-term outcomes and prognosis in a single-center experience

BACKGROUND For the management of lateral lymph node(LLN)metastasis in patients with rectal cancer,selective LLN dissection(LLND)is gradually being accepted by Chinese scholars.Theoretically,fascia-oriented LLND allows radical tumor resection and protects of organ function.However,there is a lack of studies comparing the efficacy of fascia-oriented and traditional vessel-oriented LLND.Through a preliminary study with a small sample size,we found that fasciaoriented LLND was associated with a lower incidence of postoperative urinary and male sexual dysfunction and a higher number of examined LLNs.In this study,we increased the sample size and refined the postoperative functional outcomes.AIM To compare the effects of fascia-and vessel-oriented LLND regarding short-term outcomes and prognosis.METHODS We conducted a retrospective cohort study on data from 196 patients with rectal cancer who underwent total mesorectal excision and LLND from July 2014 to August 2021.The short-term outcomes included perioperative outcomes and postoperative functional outcomes.The prognosis was measured based on overall survival(OS)and progression-free survival(PFS).RESULTS A total of 105 patients were included in the final analysis and were divided into fascia-and vesseloriented groups that included 41 and 64 patients,respectively.Regarding the short-term outcomes,the median number of examined LLNs was significantly higher in the fascia-oriented group than in the vessel-oriented group.There were no significant differences in the other short-term outcomes.The incidence of postoperative urinary and male sexual dysfunction was significantly lower in the fascia-oriented group than in the vessel-oriented group.In addition,there was no significant difference in the incidence of postoperative lower limb dysfunction between the two groups.In terms of prognosis,there was no significant difference in PFS or OS between the two groups.CONCLUSION It is safe and feasible to perform fascia-oriented LLND.Compared with vessel-oriented LLND,fascia-oriented LLND allows the examination of more LLNs and may better protect postoperative urinary function and male sexual function.

Safety and Efficacy of Racotumomab-Alum Vaccine as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer

Despite extensive clinical research in non-small cell lung cancer (NSCLC), overall survival is still poor. Racotumomab-alum is an anti-idiotypic cancer vaccine that targets NeuGcGM3 tumor associated ganglioside. The aim of this study was to evaluate safety and efficacy of racotumomab-alum in advanced NSCLC patients with progressive disease. This expanded access program included 86 histologically confirmed NSCLC patients, 18 years or older age, with advanced disease and without therapeutic option, with ECOG performance status ≤3, adequate organ functions and signed informed consent. The primary endpoint was overall survival and toxicity was measure assessed treatment-related toxicity according CTCAEv3. The study was approved by ethical review boards of participant institutions. Racotumomab-alum treatment consisted in 5 biweekly intradermal doses (1 mg/mL) during the induction phase of treatment (2 months). The maintenance phase consisted in monthly re-immunizations until unacceptable toxicity or PS worsening. The median overall survival time of all patients treated with racotumomab-alum was 8.96 months. The survival rates at 12 and 24 months were 42.8% and 28.0%, respectively. Patients that completed the induction phase of treatment (five doses or more) reached a median OS of 12.1 months. The most common adverse events were injection site reaction, bone pain, cough and asthenia. Racotumomab-alum cancer vaccine could be considered an effective and safe treatment option as second-line therapy for advanced NSCLC. Further clinical studies should be conducted to confirm this result.

Lengthening osteotomy of the fibula in treatment of treating lateral malleolar malunon

Objective To investigate the therapeutic effect of lengthening and rotational osteotomy of the fibula for lateral malleolar malunion.Methods Twenty-three patients who suffered from the traumatic arthritis of ankle were due to

Surgical treatment of the thoracic and thoracolumbar disc herniations through the posterior far lateral approach

Objective To evaluate the feasibility,safety and efficacy of surgical treatment of the thoracic and thoracolumbar disc herniations through the posterior far lateral approach.Methods From April 2005 to June 2010,24 consecutive patients

188例侧向发育型肿瘤内镜及临床病理学分析

目的总结并评价结直肠侧向发育型肿瘤(laterally spreading tumor,LST)的内镜及临床病理特征。方法回顾性分析2010年12月至2019年12月首都医科大学附属北京世纪坛医院消化内科经内镜下治疗并诊断为LST的患者,根据LST病变内镜下特点,分为颗粒型LST(granular LST,LST-G)及非颗粒型LST(non-granular LST,LST-NG)两个亚组和四个亚型,总结并分析患者的临床一般资料、内镜下特征、组织病理特征、治疗方法等相关资料。结果(1)内镜下特征:共收集176例LST患者(188处病变),LST-NG亚组病变最多,LST病变直径为(22.48±12.26)mm(10~65 mm),LST-G组病变直径大于LST-NG组(P<0.001);LST-G及LST-NG好发于升结肠,LST-G较LST-NG更好发于直肠(χ^(2)=42.360,P<0.001);NICE分类对非肿瘤性息肉及癌和癌前病变诊断的敏感性为97.9%,特异性为82.6%,Kappa值为0.820(P<0.001),NICE分型与病理金标准具有很高的一致性。(2)病理特征:LST亚组均以管状腺瘤为主,LST-NG的癌变率包括HGIN为41.9%,高于LST-G的16.7%(χ^(2)=14.63,P<0.01);LST亚组间微卫星不稳定状态、p53的表达和Ki-67增殖指数差异均无统计学意义(P>0.05)。(3)治疗方式:结肠病变多选择使用EMR及ESD治疗,直肠病变多选择ESD及手术治疗(χ^(2)=19.596,P<0.01),<20 mm的病变多选用EMR治疗,20~<30 mm的病变多选用ESD治疗,≥30 mm的病变,手术治疗的比例逐渐升高(χ^(2)=102.725,P<0.01)。结论LST的临床特性及内镜下表现存在一定的特殊性,临床应重视识别LST病变,提高LST的检出,并对于不同病变采取合适的治疗方案。

河谷区多层软土地基强夯处治分析

文章依托高速公路多层软土地基强夯处治项目,在施工现场选取具有代表性的监测断面开展现场监测,检验河谷区多层软土地基强夯处治效果。由监测数据得出,在强夯处治和路基填筑施工阶段,地基分层沉降、土压力、孔隙水压力和侧向位移增幅均较大,工后逐渐趋于稳定,可说明强夯处治后软基承载力得到有效提升,路基整体结构稳定,加固效果良好。

Effects of Nitrate on the Growth of Lateral Root and Nitrogen Absorption in Rice

Lateral root is primary organ for plant to explore and utilize soil nutrient efficiently. The development of lateral roots (LR) is controlled by both genetic factors and nutrient status in environment. To investigate the effects of nitrate (NO3-) on rice lateral root growth and nitrogen (N) uptake efficiency under upland condition, three treatments, including root-split culture and whole plant culture in N sufficient and deficient conditions, were used in a vermiculite culture experiment. Root-split treatment showed that the growth of lateral roots was stimulated by localized nitrate supply. However, in whole plant culture, elongation of lateral roots was induced by NO3- deficiency. The effects of NO3- on rice lateral root growth were genotype-dependent. Similar N concentration, soluble sugar concentration and N content in shoot were observed in both root-split treatment and whole plant culture under NO3- sufficient condition, suggesting that the nitrogen requirement for rice normal growth could be satisfied with only half of roots supplied with NO3-. In the root-split treatment, N uptake was positively correlated with the average of lateral root length (ALRL) in NO3--supplied side, suggesting that the ALRL is important for rice root N uptake in the environment where the nitrogen nutrient is limiting factor. No significant correlation was observed between N uptake and ALRL in whole plant culture under N sufficient condition, which implies that the length of lateral roots may not be the main factor to determine tire rice root N uptake in nutrient-rich zone. Morphological and metabolic evidence in this study provided some prospects for genetic improvement of root system characters to improve the efficiency of nutrient absorption in rice.

儿童侧脑室非典型畸胎瘤样/横纹肌样瘤4例

非典型畸胎瘤样/横纹肌样瘤(atypical teratoid/rhabdoid tumor, AT/RT)临床少见且预后不良,多位于幕下或皮层下方,发生于侧脑室较为罕见且预后极差,目前国内仅有6例侧脑室AT/RT相关报道。本文报道4例儿童侧脑室AT/RT患儿的诊疗经过,并通过文献复习对该病的临床表现、鉴别诊断、治疗及预后进行讨论,以提高临床医生对该病的认识,减少漏诊及误诊发生率。

呋喹替尼联合免疫检查点抑制剂在微卫星稳定型转移性结直肠癌患者后线治疗中的疗效和安全性

目的评估呋喹替尼单药或联合免疫检查点抑制剂(immune checkpoint inhibitor,ICI)在微卫星稳定(microsatellitestable,MSS)型转移性结直肠癌(metastatic colorectal cancer,mCRC)患者三线及以上治疗中的疗效和安全性。方法选择2020年1月至2024年4月在武汉大学人民医院肿瘤科接受治疗的pMMR/MSS型mCRC患者为研究对象。在未调整模型和倾向性匹配中比较呋喹替尼单药或呋喹替尼联合ICI的预后、疗效以及安全性。结果共104例患者纳入分析,其中呋喹替尼组33例,呋喹替尼联合ICI组71例。与呋喹替尼组相比,呋喹替尼联合ICI组的中位无进展生存期更长(3.0个月vs 4.5个月;HR=0.55,95%CI:0.33~0.89);但两组的中位总生存期(10.1个月vs 13.1个月)、客观缓解率(9.1%vs 11.3%)、疾病控制率(51.5%vs 66.2%)比较,差异均无统计学意义(均P>0.05)。倾向性匹配分析亦获得类似的结果。两组3级及以上不良事件均主要包括手足皮肤反应、血小板减少和白细胞减少;其中呋喹替尼组3级及以上不良事件的发生率为30.3%,呋喹替尼联合ICI组为36.6%(P=0.529)。结论相比于呋喹替尼,呋喹替尼联合ICI可为pMMR/MSS型mCRC患者的三线及以上治疗带来无进展生存期获益,安全性可控,值得进一步研究。

不同解剖修复策略改善慢性踝关节外侧不稳的网状Meta分析

目的:目前用于治疗踝外侧副韧带损伤后慢性踝关节外侧不稳的手术修复策略多样,但具体何种方式能最大程度恢复踝关节外侧稳定性仍缺乏相应的循证医学证据。基于此,文章首次采用网状Meta分析方法系统评价目前流行的4种解剖修复策略恢复慢性踝关节外侧不稳的效果。方法:计算机检索中国知网、万方数据知识服务平台、维普数据库、PubMed、Embase、Web of Science及Cochrane Library数据库,检索时限为各数据库建库至2022年12月,纳入关于不同修复策略恢复踝外侧副韧带损伤后慢性踝关节不稳的随机对照试验或临床对照试验。对文献进行筛选和资料提取,采用RevMan 5.4、R4.2以及Stata 14.2软件进行文献质量评价和数据分析。结果:纳入12项研究(其中10项随机对照试验、2项队列研究),共673例慢性踝关节不稳患者,涉及4种修复策略,观察指标为:踝关节应力位X射线片距骨前移距离与距骨倾斜角度(后文简称距骨前移距离与距骨倾斜角)。网状Meta分析结果显示:①在距骨前移距离方面,网状Meta分析排序结果从劣到优依次为解剖修补>解剖修补+下伸肌支持带加强>internal brace解剖重建>自体/同种异体肌腱解剖重建;②在距骨倾斜角方面,网状Meta分析排序结果从劣到优依次为:解剖修补>解剖修补+下伸肌支持带加强>internal brace解剖重建>自体/同种异体肌腱解剖重建。结论:自体/同种异体肌腱解剖重建策略在改善距骨前移距离方面和距骨倾斜角方面总体排序均为第一,提示此方案恢复踝外侧副韧带损伤后慢性踝关节不稳的效果可能最佳,但未来仍需更多大样本、多中心、双盲随机对照试验研究来进一步证实。